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A B S T R A C T
Multi-drug and extensively drug-resistant tuberculosis (MDR/XDR-TB) are considered a serious threat
for TB control and elimination. The outcome of these patients is still largely unsatisfactory as of today,
with treatment success rates being consistently below 50% at global level.
The World Health Organization (WHO) recommends that management of MDR-TB cases is supported
by a specialized team, including complementary medical professionals able to cover several perspectives
(clinical, both for adults and children; surgical; radiological; public health; psychological; nursing,
among others). Implementation of such a body (known as Consilium in most of the former Soviet Union
countries) is often a pre-requisite to apply for international TB control funding and concessionally priced
medicines to treat M/XDR-TB cases.
The primary objective of the ERS/WHO TB Consilium is to provide clinical consultation for drug-
resistant TB and other difﬁcult-to-treat TB cases, including co-infection with HIV and paediatric cases.
Through technical guidance to clinicians managing complex TB cases, the main contribution and
outcome of the initiative will be a public health response aimed at achieving correct treatment of
affected patients and preventing further development of drug resistance. The Consilum’s secondary
objective is to ensure monitoring and evaluation of clinical practices on the ground (diagnosis, treatment
and prevention).
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).resistant tuberculosis (XDR-TB), deﬁned as MDR-TB caused by
strains resistant to at least one ﬂuoroquinolone and one injectable
second-line anti-TB drug in addition to isoniazid and rifampicin,
has attracted interest at different levels1–5. In recent years, the
alarming rates of M/XDR-TB in Eastern Europe and other settings of
the world resulted in strong expressions of concern by national and
international health authorities, partners and scientiﬁc societies.
At media level, the key words MDR-TB and XDR-TB have caught
spikes of citations and consistent interest since the time the term
XDR-TB appeared for the ﬁrst time, as a simple Google search can
testify (Figure 1).
From the public health point of view, M/XDR-TB is considered a
serious threat for TB control and elimination. Therefore, theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. MDR-TB and XDR-TB web searches at media level (as of September 2014)
MDR-TB: multidrug-resistant tuberculosis; XDR-TB: Extensively drug-resistant tuberculosis
The numbers on the graph indicate the number of web searches performed with a speciﬁc time limit to the total number of searches done on Google over time. They do not
convey absolute values of search volume, as data are normalized and presented on a scale from 0 to 100. Each point on the graph is divided by the highest point and multiplied
by 100. If the data are not sufﬁcient, 0 is displayed. When comparing two or more elements, some bars are displayed next to the graph. The height of the bar represents the
average of all the points on the graph for that search term.
The arrow shows the year (2006) when the term XDR-TB was used for the ﬁrst time. In March 2006, following the epidemic in South Africa, the term appeared, and in
October 2006 the World Health Organization developed the consensus-based deﬁnition. The ﬁrst peak in the ﬁgure was registered in September 2006 (web search: MDR-
TB:0; XDR-TB: 31), while the highest point was in June 2007 (web search: MDR-TB:18; XDR-TB: 100).
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monitoring and evaluating prevalence and incidence rates as well
as special and temporal trends of drug resistant TB at both global
and regional level2,3.
Globally, in 2013, there were an estimated 480,000 (range:
350,000-610,000) new cases of MDR-TB. Among notiﬁed TB
patients in 2013 there were an estimated 300,000 (range:
230,000-380,000) MDR-TB cases and approximately 210,000
(range: 130,000-290,000) deaths from MDR-TB. In spite of the
notable progress in case detection, we still rely on estimates: 3.5%
of new cases and 20.5% of previously treated cases are estimated to
be affected by MDR-TB at the global level2.
The prevalence of MDR-TB is dramatically high in several
countries belonging to the former Soviet Union, where 9-35% of
new cases and 50% of previously treated cases harbor MDR-TB
strains2 (Table 1).
XDR-TB had been reported by 100 countries worldwide by the
end of 2013. A total of 75 countries and ﬁve territories reported
representative data from continuous surveillance or special
surveys regarding the proportion of MDR-TB cases affected by
XDR-TB. Combining these data, the average proportion of MDR-TBTable 1
Estimated proportion of MDR among pulmonary TB cases in Eastern Europe
countries reported in the period 2011-2013.
Country Estimated proportion
of MDR-TB among
new cases
Estimated proportion
of MDR-TB among
retreatment cases
Armenia 9.4 43
Azerbaijan 13 28
Belarus 35 55
Bulgaria 2.3 23
Estonia 17 48
Georgia 11.0 38
Kazakhstan 25 55
Kyrgyzstan 26 55
Lithuania 11 44
Republic of Moldova 24 62
Russian Federation 19 49
Tajikistan 13 56
Ukraine 14 32
Uzbekistan 23 62
TB: tuberculosis; MDR-TB: multidrug-resistant tuberculosis
Source: (Reference #2, WHO Global TB report 2014)cases harboring XDR-TB strains of M. tuberculosis was 9% (95% CI:
6.5-11.5%); they correspond to the 2012 9.6% estimates. Fifteen of
75 countries reported 10 or more XDR-TB cases in the most recent
year for which data were available. Among those countries, the
proportion of MDR-TB cases affected by XDR-TB was highest in
Georgia (20%), Kazakhstan (22.7%), Latvia (21.7%), Lithuania
(24.8%) and Tajikistan (Dushanbe city and Rudaki district: 21%)2.
In response to the alarming rates of MDR- and XDR-TB in former
Soviet Union countries, the 53 Member States of WHO European
Region have endorsed the ﬁve- year Consolidated Action Plan to
Prevent and Combat M/XDR-TB 2011-20156.
The clinical outcome of MDR-TB cases is largely unsatisfacto-
ry2,7–10 (Figure 2). In the largest ever-published cohort of 9,153
MDR-TB cases from 32 observational cohorts supporting an
individual data meta-analysis, the clinical outcomes were unac-
ceptably poor (treatment success 54%; default 23%; failure/relapse
8%; death 15%)11. In XDR-TB cases and cases with resistance
patterns beyond XDR the outcomes were even worse, with
treatment success ranging from 19% to 40%, failure/relapse from
15% to 54% and death from 15% to 35%12,13.
The challenge of providing proper treatment to M/XDR-TB
patients has been identiﬁed in several countries globally. Due to
frequent occurrence of adverse events, limited availability of
second-line anti-TB drugs, the eminent risk of acquiring further
mycobacterial resistance, associated conditions such as alcohol
and drug abuse and problems in patients’ adherence, physicians
often face major challenges to successfully treat their patients.
WHO recommends that management of MDR-TB cases is
supported by a specialized team, including complementary
medical professionals able to cover diverse perspectives (clinical,
both for adults and children; surgical; radiological; public health;
psychological; and nursing, among others). Implementation of
such a body (known as Consilium in most of the former Soviet
Union countries) is often a pre-requisite to apply for international
TB control funding and concessionally priced medicines to treat M/
XDR-TB cases.
The Green Light Committee (GLC), a WHO-hosted committee
provides technical assistance on MDR-TB management to coun-
tries through yearly country visits and on-distance support via
email or telephone. GLC ensures that MDR-TB patients are
prescribed treatment in line with the WHO guidelines, the latest
scientiﬁc evidence and country experiences. Thank to GLC’s
technical assistance, several high MDR-TB burden countries in
Figure 2. Patients diagnosed with MDR-TB: treatment outcomes, 2007–2011 cohorts (global data). The total number of cases with outcome data is shown beside each bar
MDR-TB: multidrug-resistant tuberculosis
Source: (Ref.#2, WHO Global TB report 2014).
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national level to reach consensus on the best treatment approach
for M/XDR-TB patients. However, before launching the ERS/WHO
electronic Consilium in September 2012, there were no online
mechanism to facilitate peer-to-peer consultation for individual
patient at supranational level.
However, most of these Consilia have limited experience or
cover only a fraction of the patients in the country. On the other
hand, the majority of low TB incidence countries do not have a
similar consultation body, even though, expertise to manage M/
XDR-TB cases in these settings is often limited and concentrated in
main MDR-TB reference centres.
A recent European Respiratory Society (ERS)/European Centre
for Disease Control and Prevention (ECDC) study14 highlighted
several clinical and public health MDR-TB management short-
comings in some of the low TB incidence countries of the European
Union (EU). The existence of WHO guidelines and European
Standards of TB Care seems apparently insufﬁcient to guarantee
appropriate treatment of M/XDR-TB, while rapid advice from a
multidisciplinary team with clinical and management experience
at a national or supranational level would help ensure proper
treatment15–17. In countries without a formal system of consulta-
tion, specialised staff from MDR-TB reference centres spend a
signiﬁcant proportion of their working time responding to phone
or e-mail clinical queries from all over the country and without any
formal recognition, monitoring or support for the service offered.
The WHO Regional Ofﬁce for Europe, ECDC, the UNION and
documents originating from the Wolfheze workshops (i.e. periodic
expert meeting setting the scene for improved TB control and
elimination in Europe) and national TB control programme
managers’ meetings18 recognized the signiﬁcance of national
and supranational consultation from clinical and public health’s
perspectives.
The ERS has increased its commitment towards TB control and
elimination in Europe19–22 through different initiatives, including a
public health initiative focused on the Presidential TB plan23, the
European Forum for TB innovation24, and, more recently, the Rome
consultation on TB Elimination which produced the global
consensus document ‘‘Framework for tuberculosis elimination in
low-incidence countries’’19.
To this extent and after consultation with WHO/Europe and
ECDC, and under the ERS Presidential initiative, the ERS-WHO
Electronic TB Consilium has been launched during the 30th ERS
Congress in Vienna, on September 6th, 2012. The WHO Regional
Ofﬁce for Europe signed a Memorandum of Understanding with
ERS to co-ordinate and co-manage this initiative, which has alsothe support of ECDC in public health and monitoring and
evaluation aspects.
The overarching aim of this initiative is to provide scientiﬁcally
sound and evidence-based advice to national Consilia and
individual clinicians on how to manage drug-resistant TB and
other difﬁcult-to-treat TB cases, including co-infection with HIV
and paediatric cases. Through technical guidance provided to
clinicians, the main contribution and outcome of the initiative will
be a public health response aimed at achieving correct manage-
ment of affected patients and prevention of further drug resistance
development. Its secondary objective is to ensure monitoring and
evaluation of clinical practices on the ground (diagnosis, treatment
and prevention). On top of supporting clinicians, the system will
also allow evaluating the trends in key challenges and pitfalls
which can be addressed through human resources capacity
building, including M/XDR-TB management practices (e.g. diag-
nostic and prescription habits), and clinician’s compliance with
WHO and other international, evidence-based guidelines.
The Electronic TB Consilium is particularly relevant for ERS and
ECDC, as evaluation on how the recently published EU Standards
for TB Care16,17,25 are applied is considered a priority.
The ERS/WHO TB Consilium ensures a free-cost, multi-lingual
(English, Portuguese, Russian and Spanish) internet-based consul-
tation system able to provide suggestions on clinical management
of complicated TB cases in less than 3 working days. The launch of
the initiative has been preceded by a call for experts (including TB
clinicians, but also other professionals relevant for patient
management). The expert applications have then been reviewed
and validated by a ERS/WHO/ECDC Review team based on strict
technical criteria. The electronic TB Consilium platform has been
then presented to different countries, national TB programme
managers and individual clinicians. The Consilium had been
advertised via WHO channels to National TB Programme Managers
and a presentation was done at TB STAG (Strategic Technical
Advisory Group) in Geneva; ERS addressed chest specialists
through its own publications (newsletter, European Respiratory
Journal) and its website. The Consilium has been also included in
the curriculum of the WHO Course for managers and consultants
conducted twice a year in Cepina/Sondalo, Italy, and replicated in
different continents in different languages.
Recently, a ﬁrst evaluation of the e-platform’s utilization has
been published after completing the ﬁrst 10 cases26.
The study evaluated: origin of the expert consultation’s request
(country generating the request, patient’s country of birth), clinical
questions and clinical features of the case, performance of the
platform (time to load the case, response time, need for additional
Table 2
Summary evaluation report of the ﬁrst 70 cases seeking expert advice through the
ERS/WHO Consilium
Indicator Categories Proportion/ratio
Country requesting (top 3) India 27.2%
Italy 22.7%
United Kingdom 16%
Country of birth (main) India 37%
Sex Male/female ratio 1.1
Age (mean) 31 years
Age (range) 1-68 years
Paediatric cases (number) 10 active TB 14.2%
13 Latent TB Infection 18.5%
Susceptibility of the
M. tuberculosis strain
Susceptible 26.8%
Poly-resistant 6.5%
Mono-resistant 4.3%
M/XDR-TB 56.5%
Not classiﬁable 6.5%
Pulmonary (P) and
extrapulmonary (EP) TB
Pulmonary TB 60.8%
Extra-Pulmonary TB 13.4%
P/EP TB 23.9%
Not classiﬁable 2%
Core clinical questions Treatment regimen 81.3%
Treatment duration 8.3%
Other 10.4%
Mean time to case-load 20 minutes
Average response time 41.6 hours
Repeated requests on
the same case
3 cases 6.25%
Clinician satisfaction 70 cases 100%
TB: tuberculosis; ERS: European Respiratory Society; WHO: World Health
Organization
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satisfaction (evaluated through a structured questionnaire).
The study conclusions were the following:
1. Requests came from different regions of the world, conﬁrming
that there is a global need of clinical advice for MDR-TB and
difﬁcult-to treat-cases. Requests came mainly from Europe -
with the United Kingdom being predominant (5 requests out of
10) but also from India and Vietnam;
2. Requests were mainly for adult patients (mean age: 27.9 years;
range:12-40), with 2 out of 10 cases being of pediatric interest (a
14 year old girl from Vietnam and a 12 year old girl from India,
respectively);
3. Out of the 10 cases evaluated, one was drug susceptible while
9 cases were MDR-TB (of whom 2 were XDR-TB and one pre-
XDR, e.g. MDR-TB with additional resistance to a ﬂuoroquino-
lone or aminoglycoside);
4. Six cases were pulmonary TB, while 3 were extrapulmonary and
one was both pulmonary and extrapulmonary. All of them were
bacteriologically conﬁrmed.
5. In most of the cases the clinician requested experts’ opinions
about the most suitable treatment regimen, validation of the
treatment regimen prescribed and suggested treatment dura-
tion. In a complicated case from the United Kingdom the clinical
question requested experts’ opinion for the management of
cachexia, muscle wasting and the appropriateness of surgical
treatment. In other cases, speciﬁc guidance on possible drug
interactions was requested. In one of the extrapulmonary cases
the question speciﬁcally requested how to monitor the response
to treatment and when to stop it.
6. The time needed for the clinician to upload the case into the
electronic platform was usually less than 30 minutes, with a
mean value of 20 minutes and the average response time was
40 hours. In 2 cases the experts asked the clinician to provide
further details in order to ﬁnalise their report.
7. All clinicians reported to be satisﬁed by experts’ advice.
8. Experts provided useful comments to improve the system’s
functionality. The main suggestion was aimed at improving
reporting of the new diagnostics and radiological ﬁndings, and a
better location for the (open) spaces where the clinician is
allowed to add descriptive clinical details.
9. The coordinators identiﬁed the need to allow a consolidation of
the 2 experts’ reports, in order to provide the clinician with a
perspective for the best interpretation and use of the experts’
reports. In addition the client’s satisfaction survey was added,
together with the option to invite a third expert if necessary or to
disengage an expert not providing a rapid reply. The reviewers’
pop-up directory was improved, making details available to
facilitate the choice (e.g. language spoken, specialty: pediatri-
cian, surgeon, HIV/infectious disease expert, etc).
Here we provide further update about utilization of the
Consilium platform. Seventy cases beneﬁted from the ERS/WHO
Consilium as of October 28th, 2014. There were 46 cases of active
TB requesting individual advice. In addition advice was requested
for additional 24 cases, including 4 active TB and 20 individuals
latently infected in two epidemics. In 3 cases more than one
opinion was requested to the experts, in order to ensure adequate
treatment monitoring at different stages of the patients’ roadmap
towards cure27,28 (Table 2).
India, United Kingdom and Italy are the top 3 countries
requesting the TB Consilium services, the majority of patients
(37%) being born in India. The patients were young (mean age:
31 years), with a signiﬁcant proportion of paediatric cases
(32.7%), extrapulmonary TB forms (13.4%) and M/XDR-TB cases
(56.5%).The male to female ratio was 1:1.
The majority of the clinical queries are, again, focused on the
correct selection of the treatment regimen and on its duration in
M/XDR-TB cases, TB/HIV co-infected individuals and other
difﬁcult-to-treat cases which included extrapulmonary and
paediatric TB cases27,28.
The time necessary to load the cases remained stable at
20 minutes, while the average time necessary to provide the
clinical answer to the queries by two top global TB experts has
slightly increased with the increasing number of consultations,
being now 41.6 hours. This time includes also week-ends and non-
working days, as several requests were sent on Fridays. Clients
conﬁrmed their satisfaction.
There are plans to add the translation of the platform into
French.
In addition, ERS is working to further expand the platform
functionality in different areas.
In collaboration with the WHO Regional Ofﬁce for Europe, a
new function related to trans-border migrants has recently
completed pre-testing and will be launched in 2015. It is aimed
at supporting clinicians treating trans-border migrants affected by
TB. The system will allow clinicians managing a patient in a given
country to liaise with the country where the patient is planning to
migrate during TB treatment, so that data can be exchanged and
continuum of care can be ensured. This functionality will
contribute to prevent management errors related to lack of
information on the previous patient’s medical history as well as
early treatment interruptions after the patient’s migration to a
different country/destination.
Furthermore, a new functionality is under development in
collaboration with the civil society organizations, aimed at
allowing patients to directly request speciﬁc advice for their TB
infection or disease to a physician, a nurse, a psychologist, and/or
to ask motivational support by other patients who survived the
disease.
L. D’Ambrosio et al. / International Journal of Infectious Diseases 32 (2015) 156–160160Last but not least, a new functionality is under preparation to
support clinicians and public health specialists in managing index
cases’ contacts and latently infected individuals (including those
generated by outbreaks and micro-epidemics).
A plan has been developed to increase the number of experts
serving the Consilium in its different functionalities based on the
increasing workload expected in the coming months. To cope with
the new challenges, new experts speaking Spanish, Portuguese and
Russian have been recently added to the initial pool of TB Consilum
consultants. In addition a coordinator has been identiﬁed to run
the patients’ branch, in collaboration with ELF (European Lung
Foundation), the patients’ voice supported by ERS.
At present two co-directors manage the Consilium, with the
support of one area coordinator. The number of area coordinators
will increase over time, to ensure timely response to the query
posed.
All the TB Consilium functionalities have been developed based
on the requirements of the Swiss legislation in force.
This new system will represent an effective instrument able to
support the new WHO End -TB Strategy focused on the concept of
TB pre-elimination (deﬁned as <10 TB cases per million popula-
tion) and TB elimination (deﬁned as <1 TB case per million)19–21.
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